Three African organizations — Biolinx Africa, YTO Foundation, and Nextgen Molecular Lab — have pooled $3.5 million in African capital to finance a large‑scale genomics project in Kenya and Côte d’Ivoire. The initiative, announced at the World Health Summit Regional Meeting in Nairobi, marks a milestone in African‑funded scientific infrastructure.
The partnership will acquire an Illumina NovaSeq X Plus sequencing platform, strengthening Africa’s genomic research and pharmacogenomics capabilities. Researchers say the project aims to improve health sovereignty and reduce reliance on foreign‑controlled biological data and infrastructure.
Africa carries 25% of the global disease burden, yet contributes less than 2% of global genomic data. This underrepresentation has led to challenges in healthcare, including inaccurate diagnoses and drug dosages based on non‑African datasets. By generating local genomic data, the initiative seeks to ensure “the right drug, for the right patient, at the right dose.”
The first phase will run for 24 months, focusing on sequencing capacity in Kenya and Côte d’Ivoire. The countries were chosen for their genetic diversity — Kenya as the anatomical origin of modern humans, and Côte d’Ivoire for its ancestral links to Afro‑American populations.
Beyond science, the project emphasizes economic returns. Promoters estimate that each dollar invested in genomics could generate up to $400 in value across bioinformatics, diagnostics, drug development, and pharmaceutical industries.
The initiative also prioritizes decentralized infrastructure to avoid healthcare inequality, ensuring that genomic facilities extend beyond major cities. It builds on existing networks like H3Africa and the Africa CDC Pathogen Genomics Initiative, both of which have expanded sequencing capacity across the continent.
For African researchers, this partnership represents a step toward scientific autonomy, reducing dependence on foreign labs and ensuring that African populations benefit directly from their own biological data.
